Myeloproliferative Neoplasms (MPN)

Rusfertide Cuts Phlebotomy Need in Polycythemia Vera: Andrew Kuykendall, MD

Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation

Understanding Hematocrit Thresholds in Polycythemia Vera Treatment

Managing Polycythemia Vera to Reduce Risks and Improve Lives

The Challenge of Managing Both Disease Symptoms and Drug Side Effects in Myelofibrosis

Options for MPN Treatment Are Expanding Rapidly With More on the Horizon

Patient-Reported Outcomes Drive Effective MPN Treatment

The Importance of Symptomatic Improvement in MPN

Treatment Differences for Younger vs Older Patients With MPNs

New Data Challenge Traditional Treatment Paradigm in MPNs, Says Dr Raajit Rampal